Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V.

Boehringer Mannheim Gmbh

Other

Atc Dr. Mann

Fraunhofer

Herwig Brunner

Afroditi Kapurniotu

J&uuml;rgen Bernhagen

Hans Seidel

Jürgen Bernhagen

Frank Vitzthum

Wolfgang Gruber

Klaus Beaucamp

Helmgard Gauhl

Thomas Schiestel

Michael Nelboeck

Jurgen Bernhagen

Georg Geiger

Günter Tovar

Ralf Mischke

Robert Kleemann

Stephan Fischer

Klaus Pfizenmaier

Matthias Grell

Peter Stahl

Georg-Burkhard Kresse

Norbert Stroh

Steffen Rupp

Andreas Wolf

Peter Scheurich

Hans-Otto Beutler

Anke Burger-Kentischer

Achim Weber

Günther Mann

Heike Mertsching

Bridgitte Koch-Pelster

Doris Finkelmeier

Barbel Wurst

Xin Xiong

Nicole Hauser

Angela Hammer

Gu Nter Tovar

Bentsian Elkine

Jürgen Schmucker

Manfred Kühn

Elkin Bentsian

Xiulian Pan

Eckehard Kuhn

Stefan Kiesewetter

Henrike Lotz

The present invention relates to methods for screening molecules and methods to detect protein-protein interactions and means used therein. More specifically, the present invention relates to methods for screening candidate drugs for treating or detecting MIF (macrophage migration inhibitor factor) related diseases. In certain aspects, the present invention involves detecting MIF/Jab1 (c-Jun activation domain binding protein) interactions as a basis for modulating cellular regulatory pathways and for identifying candidate drugs for MIF-related diseases. The invention also provides methods for the identification of molecules which dissociate or prevent interaction or binding between MIF and Jab1.

Anti-MIF antibodies

The present invention concerns isolated collagen, the method for its production, and isolation of the collagen from collagen-containing tissues, as well as the use of the isolated collagen in a biomatrix as an in vitro test system, tissue replacement or organ replacement.

Isolated nature-identical collagen

The present invention relates to nanoparticles with tumor necrosis factor (TNF) or cytokine immobilized thereon, where TNF or the cytokine is preferably immobilized in the form of a trimer in directed fashion and with retention of its biological activity on the carrier, to methods for the directed immobilization of TNF or cytokine on nanoparticles, to the use of the nanoparticles having immobilized TNF or cytokine for the identification and/or isolation of cytokine- or TNF-binding partners and for the identification and/or isolation of inhibitors of the interaction between TNF or cytokine and its binding partners, to the use of such nanoparticles for preparing a pharmaceutical composition, in particular for the therapy of tumors, and to pharmaceutical and diagnostic compositions which comprise such nanoparticles.

Nanoparticles comprising biologically active TNF which is immobilized on the same

The invention concerns a peptide having the biological activity of an inhibitor of amyloid formation and its diagnostic and medical use.

Soluble cyclic analogues of &#x3b2; amyloid peptide

Screening method for candidate drugs

The present invention relates to an improved method for mass spectrometric analysis, in particular for matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) using nanoparticles, where an analyte is added to a nanoparticle suspension, and the suspension containing the bound analyte is then deposited directly on a MALDI sample carrier and investigated by mass spectrometry, and to nanoparticles suitable for this method.

Mass spectrometric analysis using nanoparticles

The invention relates to an efficient process and device for the decontamination of waters polluted with heavy metals, semimetals and/or radionuclides by cation exchange and electrochemical deposition of the anions.

Method and device for decontaminating water which contains metal and/or is radioactively contaminated

A metal solution-diffusion membrane of a macroporous base on which a thin metal membrane layer is formed is disclosed. In the membrane, the base includes a hollow fiber with a metal material containing an intermediate layer being formed between the hollow fiber and the metal membrane layer. The metal solution-diffusion membrane can be made with a very thin metal membrane layer with high permeability and possesses long-term stability as well as a great separation surface/volume ratio. A method for producing a metal solution-diffusion membrane in which the intermediate layer serves to provide nuclei for the subsequent currentless deposition of the metal layer is also disclosed.

Metal solution-diffusion membrane and method for producing the same

The present invention relates to metal-containing ribonucleotide polypeptides (RNP) and processes for their production, their use and medicaments containing ribonucleotide polypeptides or their molecular-biological equivalent structures and/or parts and/or derivatives.

Metal-containing ribonucleotide polypeptides

The present invention relates to a method and an apparatus for separating substances from or in biological materials.

Method and sample mount system for the in situ separation and enrichment of substances

Calcitonins and calcitonin derivatives such as are employed for therapy for, for example, osteoporosis. Paget's disease or hypercalcemia. The calcitonins and calcitonin derivatives are distinguished by a bridging of the amino acids present in the positions 17 and 21. In this case, by means of a suitable choice of the amino acids present in these positions an 18- or 19-membered ring is produced. This ring leads to an increased conformational stability and to an increased activity of the modified calcitonin. A particularly suitable hCt (human Ct) analog is the cyclo -&lsqb;Asp , Orn &rsqb;-hCt according to the invention having a 19-membered ring structure between the lactam-bridged Asp and Orn .

Superpotent calcitonin analogs having greatly increased hypocalcemic action in vivo

The invention relates to a method and a device for the isolation and purification of nucleic acids. According to the invention, after decomposition of a sample the nucleic acids present in said sample are isolated and purified.

Electrical integrated nucleic acid isolation, purification and detection

The patent relates to a method for spectroscopic and spectrofluorimetric determination of the interaction between materials. The determination takes place using apparatus consisting of several basins.

Method for differential spectroscopic measurements

Certain peptide molecules can be used as the basic structures (template molecules) for inhibiting and analysing amyloid formation and cytotoxicity in amyloid illnesses. These peptides have an effect on the molecules which are responsible for the amyloid illnesses (for their part amyloid-forming peptides and proteins). The peptides are thus either inhibitors themselves or agonists of amyloid formation and cytotoxicity or can serve as a template for identifying and producing further inhibitors and agonists and can be used as molecular tools during analysis. The peptide molecules have generally 3-15 amino acids, and preferably a maximum of 10 amino acids, and at least an active peptide sequence GA, preferably GAI, and even more preferably one selected from the group consisting of GAIL, SEQ ID NO: 1; FGAIL, SEQ ID NO: 2; NFGAIL, SEQ ID NO: 3; NNFGAIL, SEQ ID NO: 4; SNNFGAIL, SEQ ID NO: 5; NFGAILSS, SEQ ID NO: 6; SNNFGAILSS, SEQ NO: 7; or the group consisting of GAII, SEQ ID NO: 8; KGAII, SEQ ID NO: 9; NKGAII, SEQ ID NO: 10; SNKGAII, SEQ ID NO: 11; GSNKGAII, SEQ ID NO: 12; NKGAIIGL, SEQ ID NO: 13; GSNKGAIIGL, SEQ ID NO: 14; or the group consisting of GAVV, SEQ ID NO: 15; AGAVV, SEQ ID NO: 16; VAAGAVV, SEQ ID NO: 17; HVAAGAVV, SEQ ID NO: 18; AAGAVVGG, SEQ ID NO: 19; HVAAGAVVGG, SEQ ID NO: 20; AAGAVV, SEQ ID NO: 21. The peptide sequence generally has at least one hydrogen molecule, and preferably every second hydrogen molecule, of an amide bond replaced by a methyl group.

Peptides used as agonists and/or inhibitors of amyloid formation and cytotoxicity and also for use in alzheimer's disease, in type II diabetes mellitus and in spongiform encephalophathies

Superpotent calcitonin analogs have greatly increased hypocalcemic action in vivo. These calcitonins and calcitonin derivatives are employed for the therapy of, for example, osteoporosis, Paget's disease or hypercalcemia. The calcitonins and calcitonin derivatives are distinguished by a bridging of the amino acids present in the positions 17 and 21. By means of suitable choice of the amino acids present in these positions an 18-membered or 19-membered ring is produced. This ring leads to an increased conformational stability and to an increased activity of the modified calcitonin. A particularly suitable hCt (human calcitonin analog) is a cyclo,-&lsqb;Asp,, Orn,&rsqb;-hCt having a 19-membered ring structure between the lactam-bridged Asp,and Orn,.

Growing community of inventors

Stuttgart, Germany

Herwig Brunner